A gigantic merger may be on the way, if the Financial Times' anonymous sources are to be believed, between the Swedish-British pharmaceutical giant Astrazeneca and its American counterpart Bristol Myers Squibb.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
A gigantic merger may be on the way, if the Financial Times' anonymous sources are to be believed, between the Swedish-British pharmaceutical giant Astrazeneca and its American counterpart Bristol Myers Squibb.